Report of Foreign Issuer (6-k)
February 02 2015 - 6:10AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of February, 2015
Commission File Number
Novogen
Limited
(Translation of registrants name into English)
16-20 Edgeworth David Ave, Hornsby, NSW 2077, Australia
(Address of principal executive office)
Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F þ Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted
solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7): ¨
Note: Regulation S-T Rule 101(b)(7) only
permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated,
domiciled or legally organized (the registrants home country), or under the rules of the home country exchange on which the registrants securities are traded, as long as the report or other document is not a press release, is
not required to be and has not been distributed to the registrants security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.
Indicate by check mark if the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission
pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes ¨ No þ
If yes is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b)
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
Novogen Limited (Registrant)
Lionel Mateo
Lionel Mateo
Company Secretary
Date 2 February 2015
|
|
|
|
|
ASX:NRT
NASDAQ:NVGN
Novogen Ltd (Company)
ABN 37 063 259 754
Capital Structure
Ordinary Shares on issue:
246 M
Board of
Directors Dr Graham Kelly
Chairman & Executive Director
Steve Coffey Non Executive Director
John OConnor
Non Executive Director
Prof Peter Gunning Non Executive Director |
|
MARKET RELEASE February 2,
2015 Novogen to present at BIO & CEO Investor Conference 9th & 10th February, 2015
New York, NY: Novogen Limited (ASX:NRT; NASDAQ:NVGN) is pleased to announce that Novogen Group CEO and Executive Chairman, Graham Kelly PhD, will
be presenting at the 17th annual BIO CEO and Investor Conference being held on the 9th &
10th February, 2015. The
conference is the largest of its kind, focusing on established and emerging publicly listed biotech companies and is attended by a mix of investors, analysts, investment bankers and industry.
Dr Kelly will outline the Companys two proprietary drug technology platforms and
their potential therapeutic value in oncology, as well as reviewing the Companys clinical strategy and timetable and anticipated milestones.
Kelly, said, The BIO CEO and Investor conference presents an opportunity for Novogen to bring its unique story to the attention of the market. Novogen is
different. The path we have chosen to take is different because current standard and experimental approaches are failing to address the causes of cancer recurrence: the impregnability of the cancer stem cell and the ability of a cancer to survive by
continuing to mutate and produce means of beating new therapies. With one
technology platform with a potent ability to kill cancer stem cells and a second platform that produces dramatic synergy of some of the most widely used and effective cytotoxics in chemotherapy, we believe we have the potential to make meaningful
differences to the lives of patients with malignant cancers. |
|
Date & Time:
Venue: |
|
9th February, 2015,
9am The Waldorf Astoria, New York,
4th Floor, Duke of Windsor Room |
|
|
|
|
About the Bio CEO & Investor Conference
The 17th Annual BIO CEO & Investor Conference is the largest independent investor conference focused
on publicly-traded biotechnology companies. The conference is designed to foster an informative dialogue between institutional investors and senior biotechnology executives about emerging and current investment opportunities. The 2014 CEO &
Investor Conference featured 1,820 partnering meetings, 149 company presentations, and 1,400 attendees, over half of which were investors. |
Page | 2
About Novogen Limited
Novogen is a public, Australian drug-development company whose shares trade on both the Australian Securities Exchange (NRT) and NASDAQ
(NVGN). The Novogen Group includes a New Haven CT based joint venture company, CanTx Inc., with Yale University.
Novogen has two main
drug technology platforms: super-benzopyrans (SBPs) and anti-tropomyosins (ATMs). SBP compounds have been created to kill the full range of cells within a tumor, but particularly the cancer stem cells. The ATM compounds target the microfilament
component of the cancer cell and when used in conjunction with standard anti-microtubular drugs, result in comprehensive and fatal destruction of the cancer cells cytoskeleton. Ovarian cancer, colorectal cancer, malignant ascites, prostate
cancer, neural cancers (glioblastoma, neuroblastoma in children) and melanoma are the key clinical indications being pursued, with the ultimate objective of employing both technologies as a unified approach to first-line therapy.
Further information is available on our websites www.novogen.com
For more information please contact:
|
|
|
Corporate Contact Dr. Graham Kelly
Executive Chairman & CEO Novogen Group
Graham.Kelly@novogen.com +61 (0) 2 9472 4100 |
|
Media Enquiries Cristyn Humphreys
Chief Operating Officer Novogen Group
Cristyn.Humphreys@novogen.com +61 (0) 2 9472
4111 |
Forward Looking Statement
This press release contains forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and section 21E of the
Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as expects, appear, intends, hopes, anticipates,
believes, could, should, would, may, target, evidences and estimates, and other similar expressions, but these words are not the exclusive means of
identifying such statements. Such statements include, but are not limited to any statements relating to the Companys drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the
Companys drug development program, including, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the
difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Companys drug components, including, but not limited to the ability of the Company to procure additional future sources of
financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Companys drug compounds, including, but not limited to events that could slow or prevent products coming to market, the uncertainty of patent protection for
the Companys intellectual property or trade secrets, including, but not limited to, the intellectual property relating to the Companys two proprietary technology platforms, and other risks detailed from time to time in the filings
the Company makes with Securities and Exchange Commission including its annual reports on Form 20-F and its reports on Form 6-K. Such statements are based on managements current expectations, but actual results may differ materially due
to various factions including those risks and uncertainties mentioned or referred to in this press release. Accordingly, you should not rely on those forward-looking statements as a prediction of actual future results.
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Jul 2023 to Jul 2024